靶向ROBO1 CAR T细胞治疗胶质母细胞瘤的轴突导向依赖性
本研究通过整合基因组分析、全基因组遗传扰动筛选及多种验证,发现复发性胶质母细胞瘤(GBM)存在一致的特定遗传依赖,PTP4A2经与ROBO1的去磷酸化轴调控自我更新、增殖与致瘤性。由于泛PTP4A抑制剂血脑屏障穿透性差,研究者构建靶向ROBO1的第二代CAR T细胞;单剂ROBO1 CAR T细胞使复发性GBM细胞系来源异种移植(CDX)模型的中位生存期翻倍,在成人肺转移至脑的CDX模型及儿童复发髓母细胞瘤CDX模型中,50-100%小鼠肿瘤被清除。
要点
- 复发性GBM存在跨模型一致的遗传依赖,伴突变负荷增加及转录与蛋白表达差异。
- PTP4A2经与ROBO1的去磷酸化轴调控复发性GBM的自我更新、增殖和致瘤性。
- 单剂ROBO1 CAR T细胞使复发性GBM的CDX模型中位生存期翻倍,并在其他脑肿瘤CDX模型中清除肿瘤。
核心结论
- 复发性GBM存在由PTP4A-ROBO1信号轴驱动的多层遗传反应,靶向ROBO1的CAR T细胞在多种CDX模型中显示抗肿瘤作用,作者认为该轴在其它恶性脑肿瘤中具有潜在应用价值。
研究设计与样本
- 研究采用整合基因组分析、患者来源GBM模型的全基因组遗传扰动筛选及独立验证,并构建靶向ROBO1的第二代CAR T细胞,在CDX模型(复发性GBM、成人肺转移至脑、儿童复发髓母细胞瘤)中评估。
主要发现
- 复发性肿瘤模型与初发GBM相比突变负荷增加并存在转录与蛋白表达差异,特定遗传依赖在复发性肿瘤模型中一致。
- PTP4A2的遗传扰动或小分子抑制经与ROBO1的去磷酸化轴发挥作用,利用对ROBO信号的依赖性。
- 单剂ROBO1 CAR T细胞使复发性GBM的CDX模型中位生存期翻倍。
- 在成人肺转移至脑及儿童复发髓母细胞瘤的CDX模型中,ROBO1 CAR T细胞在50-100%的小鼠中清除肿瘤。
临床怎么用
- 泛PTP4A抑制剂因体内血脑屏障穿透性差而受限,作者据此构建靶向ROBO1的第二代CAR T细胞;原文未据此给出临床推荐。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Resistance to genotoxic therapies and tumor recurrence are hallmarks of glioblastoma (GBM), an aggressive brain tumor. In this study, we investigated functional drivers of post-treatment recurrent GBM through integrative genomic analyses, genome-wide genetic perturbation screens in patient-derived GBM models and independent lines of validation. Specific genetic dependencies were found consistent across recurrent tumor models, accompanied by increased mutational burden and differential transcript and protein expression compared to its primary GBM predecessor. Our observations suggest a multi-layered genetic response to drive tumor recurrence and implicate PTP4A2 (protein tyrosine phosphatase 4A2) as a modulator of self-renewal, proliferation and tumorigenicity in recurrent GBM. Genetic perturbation or small-molecule inhibition of PTP4A2 acts through a dephosphorylation axis with roundabout guidance receptor 1 (ROBO1) and its downstream molecular players, exploiting a functional dependency on ROBO signaling. Because a pan-PTP4A inhibitor was limited by poor penetrance across the blood-brain barrier in vivo, we engineered a second-generation chimeric antigen receptor (CAR) T cell therapy against ROBO1, a cell surface receptor enriched across recurrent GBM specimens. A single dose of ROBO1-targeted CAR T cells doubled median survival in cell-line-derived xenograft (CDX) models of recurrent GBM. Moreover, in CDX models of adult lung-to-brain metastases and pediatric relapsed medulloblastoma, ROBO1 CAR T cells eradicated tumors in 50-100% of mice. Our study identifies a promising multi-targetable PTP4A-ROBO1 signaling axis that drives tumorigenicity in recurrent GBM, with potential in other malignant brain tumors.
引用
- Chokshi CR, Shaikh MV, Brakel B, et al. Targeting axonal guidance dependencies in glioblastoma with ROBO1 CAR T cells. Nat Med. 2024. PMID: 39095594. doi:10.1038/s41591-024-03138-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。